Definium Therapeutics' (DFTX) Buy Rating Reiterated at Needham & Company LLC

Key Points

• Needham reaffirmed a Buy rating on Definium Therapeutics with a $66 price target, implying 69.71% potential upside from the prior close. The stock has a consensus Buy rating and an average analyst target of $63.
• Definium reported quarterly adjusted EPS of -$1.44, missing the consensus estimate of -$0.55; analysts expect a full-year loss of approximately $3.02 per share.
• Insiders sold 67,119 shares worth about $2.9 million over the past three months, while institutional investors own 27.91% of the company.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a report issued on Monday, Benzinga reports. They presently have a $66.00 target price on the stock. Needham & Company LLC's target price would indicate a potential upside of 69.71% from the company's previous close.

A number of other equities analysts also recently weighed in on DFTX. Stifel Nicolaus boosted their target price on Definium Therapeutics from $30.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Wells Fargo & Company upped their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a research note on Thursday, August 13th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an "outperform" rating in a research note on Monday, June 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $63.00.

Definium Therapeutics Stock Performance

Shares of Definium Therapeutics stock opened at $38.89 on Monday. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average price of $43.01 and a 200-day moving average price of $30.33. Definium Therapeutics has a 52 week low of $8.77 and a 52 week high of $49.70. The company has a market cap of $5.23 billion, a PE ratio of -11.34 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts anticipate that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer directly owned 1,098,246 shares of the company's stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider directly owned 320,571 shares of the company's stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 67,119 shares of company stock worth $2,887,496 over the last three months. Company insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors have recently made changes to their positions in the business. Nykredit A S bought a new stake in Definium Therapeutics in the second quarter worth $45,000. Allworth Financial LP purchased a new stake in Definium Therapeutics during the 2nd quarter valued at about $110,000. Integrated Wealth Concepts LLC purchased a new stake in Definium Therapeutics during the 2nd quarter valued at about $159,000. Russell Investments Group Ltd. grew its position in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Definium Therapeutics in the 2nd quarter worth approximately $222,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.